Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ARVN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 22, 2026
Report Source: 2026 1st Quarter Report
Arvinas Inc. Stock Analysis ARVN
United States Health Care Small Cap Report: Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Read More Arvinas Inc (ARVN) Chart
Key Statistics of Arvinas Inc (ARVN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$7.63Volume
852.17KP/E Ratio (TTM)
-52 Week Range
Market Cap
587.14MAvg. Volume
737.40KDividend Yield
-Financial Metrics & Statements of Arvinas Inc (ARVN)
FAQ's for Arvinas Inc (ARVN)
- According to Musaffa’s Shariah screening methodology, Arvinas Inc (ARVN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Arvinas Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Arvinas Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Arvinas Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Arvinas Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Arvinas Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.